0001035422false--12-31Q320260.00011000000000000.00011500000005883723261516676falsefalsefalsefalse1150000115000011500001120001120001120000.100.1000010354222026-01-012026-09-300001035422country:US2026-01-012026-08-110001035422ctth:UnitaryPatentMember2026-01-012026-09-300001035422country:GB2026-01-012026-09-300001035422ctth:UsThreeCountryMember2026-01-012026-09-300001035422country:MX2026-01-012026-09-300001035422ctth:EuropeCountryMember2026-01-012026-09-300001035422ctth:UsTwoCountryMember2026-01-012026-09-300001035422ctth:CanadaOneCountryMember2026-01-012026-09-300001035422ctth:UsOneCountryMember2026-01-012026-09-300001035422country:CA2026-01-012026-09-300001035422country:US2026-01-012026-09-300001035422ctth:FrankHaritonMember2026-09-300001035422ctth:KevinSakserMember2026-09-300001035422ctth:ShayKerenMember2026-09-300001035422ctth:RyanKhouriMember2026-09-300001035422ctth:RyanKhouriMember2026-07-012026-09-300001035422ctth:KatherineColeAndKevinSakserMember2026-01-012026-03-310001035422ctth:KevinSakserMember2026-01-012026-09-300001035422ctth:FrankHaritonMember2026-01-012026-09-300001035422ctth:RyanKhouriMember2026-01-012026-09-300001035422ctth:ChristopherSellbergAndRobertJensenMember2026-01-012026-09-300001035422ctth:KevinSakserMember2026-07-012026-09-300001035422ctth:RobertJensenMember2026-07-012026-09-300001035422ctth:ShayKerenMember2026-07-012026-09-300001035422ctth:ChristopherSellbergMember2026-07-012026-09-300001035422ctth:FrankHaritonMember2026-07-012026-09-300001035422ctth:ShayKerenMember2026-01-012026-09-300001035422ctth:PetroCzupielMember2024-01-012024-12-310001035422ctth:JohnJenneweinMember2024-01-012024-12-310001035422ctth:AllenGreenspoonMember2024-01-012024-12-310001035422ctth:KevinSakserMember2024-01-012024-12-310001035422ctth:RyanKhouriMember2024-01-012024-12-3100010354222024-01-012024-12-310001035422ctth:FrankHaritonMember2025-01-012025-12-310001035422ctth:BordersConsultingLLCMember2025-01-012025-12-310001035422ctth:MurrayGoldenbergMember2025-01-012025-12-310001035422ctth:KevinSakserMember2025-01-012025-12-310001035422ctth:KatherineColeMember2025-01-012025-12-310001035422ctth:RyanKhouriMember2025-01-012025-12-310001035422ctth:KevinSakserMember2026-01-012026-03-310001035422ctth:KatherineColeMember2026-01-012026-03-310001035422ctth:RyanKhouriMember2026-01-012026-03-3100010354222026-01-012026-03-3100010354222025-01-012025-12-310001035422us-gaap:TrademarksMember2026-01-012026-09-300001035422us-gaap:PatentsMember2026-01-012026-09-3000010354222024-12-3100010354222025-01-012025-09-300001035422us-gaap:RetainedEarningsMember2026-09-300001035422us-gaap:TreasuryStockCommonMember2026-09-300001035422us-gaap:AdditionalPaidInCapitalMember2026-09-300001035422us-gaap:CommonStockMember2026-09-300001035422us-gaap:RetainedEarningsMember2026-07-012026-09-300001035422us-gaap:TreasuryStockCommonMember2026-07-012026-09-300001035422us-gaap:AdditionalPaidInCapitalMember2026-07-012026-09-300001035422us-gaap:CommonStockMember2026-07-012026-09-3000010354222026-06-300001035422us-gaap:RetainedEarningsMember2026-06-300001035422us-gaap:TreasuryStockCommonMember2026-06-300001035422us-gaap:AdditionalPaidInCapitalMember2026-06-300001035422us-gaap:CommonStockMember2026-06-3000010354222025-09-300001035422us-gaap:RetainedEarningsMember2025-09-300001035422us-gaap:TreasuryStockCommonMember2025-09-300001035422us-gaap:AdditionalPaidInCapitalMember2025-09-300001035422us-gaap:CommonStockMember2025-09-300001035422us-gaap:RetainedEarningsMember2025-07-012025-09-300001035422us-gaap:TreasuryStockCommonMember2025-07-012025-09-300001035422us-gaap:AdditionalPaidInCapitalMember2025-07-012025-09-300001035422us-gaap:CommonStockMember2025-07-012025-09-3000010354222025-06-300001035422us-gaap:RetainedEarningsMember2025-06-300001035422us-gaap:TreasuryStockCommonMember2025-06-300001035422us-gaap:AdditionalPaidInCapitalMember2025-06-300001035422us-gaap:CommonStockMember2025-06-3000010354222025-07-012025-09-3000010354222026-07-012026-09-3000010354222025-12-3100010354222026-09-30iso4217:USDxbrli:sharesiso4217:USDxbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
☒ | QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended September 30, 2026
☐ | TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from _________ to _________
Commission file number: 333-292497
CTT PHARMACEUTICAL HOLDINGS, INC. |
(Exact name of registrant as specified in its charter) |
Florida | | 11-3763974 |
(State or other jurisdiction of incorporation or organization) | | (I.R.S. Employer Identification No.) |
| | |
1646 W Snow Avenue Suite 138, Tampa, FL | | 33606 |
(Address of principal executive offices) | | (Zip Code) |
(813) 606-0060
(Registrant’s telephone number, including area code)
Indicate by checkmark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer”, “non-accelerated filer”, “emerging growth company” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one).
Large accelerated filer | ☐ | Accelerated filer | ☐ |
Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
| | Emerging growth company | ☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of September 30, 2026, there were 61,516,676 shares outstanding of the registrant’s common stock.
PART I—FINANCIAL INFORMATION
CTT PHARMACEUTICAL HOLDINGS, INC.
FINANCIAL STATEMENTS
SEPTEMBER 30, 2026
(unaudited)
Balance Sheets | Income Statements | Statements of Stockholders' Equity | Statements of Cash Flow | Notes to the Financial Statements
CTT PHARMACEUTICAL HOLDINGS, INC.
Balance Sheets
As of September 30, 2026 and December 31, 2025
(unaudited)
| | September 30, | | | December 31, | |
| | 2026 | | | 2025 | |
Assets | | | | | | |
| | | | | | |
Current assets | | | | | | |
Cash | | $ | 12,625 | | | $ | 15,359 | |
Total current assets | | | 12,625 | | | | 15,359 | |
| | | | | | | | |
Non-current assets | | | | | | | | |
Intangible assets, net | | | 65,701 | | | | 70,809 | |
Total non-current assets | | | 65,701 | | | | 70,809 | |
| | | | | | | | |
Total Assets | | $ | 78,326 | | | $ | 86,168 | |
| | | | | | | | |
Liabilities and Stockholders' Equity | | | | | | | | |
| | | | | | | | |
Current liabilities | | | | | | | | |
Related-party payables | | $ | 17,905 | | | $ | 12,204 | |
Related-party note payable | | | 19,442 | | | | 18,814 | |
Total current liabilities | | | 37,347 | | | | 31,018 | |
| | | | | | | | |
Stockholders' equity | | | | | | | | |
Preferred stock, $0.0001 par value; 10,000,000 authorized; none issued and outstanding as of September 30, 2026 and December 31, 2025 | | | - | | | | - | |
Common stock, $0.0001 par value; 150,000,000 shares authorized; 61,516,676 and 58,837,232 issued and outstanding as of September 30, 2026 and December 31, 2025 | | | 6,152 | | | | 5,884 | |
| | | | | | | | |
Additional paid-in capital | | | 7,813,262 | | | | 7,600,729 | |
Accumulated deficit | | | (7,778,435 | ) | | | (7,551,463 | ) |
Total stockholders' equity | | | 40,979 | | | | 55,150 | |
| | | | | | | | |
Total liabilities and stockholders' equity | | $ | 78,326 | | | $ | 86,168 | |
See accompanying notes, which are an integral part of these financial statements.
CTT PHARMACEUTICAL HOLDINGS, INC.
Income Statements
For the three months ended September 30, 2026 and September 30, 2025
(unaudited)
| | September 30, | | | December 31, | |
| | 2026 | | | 2025 | |
| | | | | | |
Operating expenses | | | | | | |
Consulting fees | | $ | 112,000 | | | $ | 5,000 | |
General and administrative costs | | | 2,314 | | | | 9,374 | |
Filing and legal costs | | | 13,645 | | | | 1,005 | |
Other business expenses (net recovery) | | | (2,985 | ) | | | - | |
Bank charges | | | 169 | | | | - | |
Travel | | | 51 | | | | - | |
Meals | | | 252 | | | | - | |
Marketing and promotions | | | 46 | | | | - | |
Amortization expense | | | 1,703 | | | | - | |
Total operating expenses | | | 127,195 | | | | 15,379 | |
| | | | | | | | |
Other income | | | | | | | | |
Interest and rewards income | | | 131 | | | | - | |
| | | | | | | | |
Net (loss) | | $ | (127,064 | ) | | $ | (15,379 | ) |
| | | | | | | | |
Basic and diluted loss per share | | $ | (0.00 | ) | | $ | (0.00 | ) |
| | | | | | | | |
Weighted average shares outstanding | | | | | | | | |
Basic and diluted | | | 60,695,179 | | | | 57,327,232 | |
See accompanying notes, which are an integral part of these financial statements.
CTT PHARMACEUTICAL HOLDINGS, INC.
Statements of Stockholders' Equity
For the three months ended September 30, 2026 and September 30, 2025
(unaudited)
| | Common | | | Additional Paid-in | | | Treasury | | | Accumulated | | | Total | |
| | Shares | | | Par Value | | | Capital | | | Stock | | | Deficit | | | Equity | |
Balances, July 1, 2026 | | | 59,722,232 | | | $ | 5,973 | | | $ | 7,671,441 | | | $ | - | | | $ | (7,651,371 | ) | | $ | 26,043 | |
Net loss for the three months | | | - | | | | - | | | | - | | | | - | | | | (127,064 | ) | | | (127,064 | ) |
Common shares issued for services | | | 1,150,000 | | | | 115 | | | | 111,885 | | | | - | | | | - | | | | 112,000 | |
Common shares issued for cash | | | 644,444 | | | | 64 | | | | 29,936 | | | | - | | | | - | | | | 30,000 | |
Balances, September 30, 2026 | | | 61,516,676 | | | $ | 6,152 | | | $ | 7,813,262 | | | $ | - | | | $ | (7,778,435 | ) | | $ | 40,979 | |
| | | | | | | | | | | | | | | | | | | | | | | | |
Balances, July 1, 2025 | | | 57,327,232 | | | $ | 5,732 | | | $ | 7,562,236 | | | $ | - | | | $ | (7,485,829 | ) | | $ | 82,139 | |
Net loss for the three months | | | - | | | | - | | | | - | | | | - | | | | (15,379 | ) | | | (15,379 | ) |
Common shares issued for cash | | | - | | | | - | | | | 15,000 | | | | - | | | | - | | | | 15,000 | |
Balances, September 30, 2025 | | | 57,327,232 | | | $ | 5,732 | | | $ | 7,577,236 | | | $ | - | | | $ | (7,501,208 | ) | | $ | 81,760 | |
See accompanying notes, which are an integral part of these financial statements.
CTT PHARMACEUTICAL HOLDINGS, INC.
Statements of Cash Flows
For the nine months ended September 30, 2026 and September 30, 2025
(unaudited)
| | September 30, | | | September 30, | |
| | 2026 | | | 2025 | |
| | | | | | |
Cash flows from operating activities | | | | | | |
Net (loss) | | $ | (226,972 | ) | | $ | (105,652 | ) |
Adjustments to reconcile net loss to cash used in operating activities | | | | | | | | |
Amortization expense | | | 5,109 | | | | 4,800 | |
Common shares issued for services | | | 172,000 | | | | 60,120 | |
Changes in accounts payable and accrued expenses | | | 5,701 | | | | (19,926 | ) |
Accrued interest | | | 628 | | | | 470 | |
Net cash provided (used) by operating activities | | | (43,534 | ) | | | (60,188 | ) |
| | | | | | | | |
Cash flows from investing activities | | | | | | | | |
Patent costs - deferred | | | - | | | | (4,491 | ) |
Net cash provided (used) by investing activities | | | - | | | | (4,491 | ) |
| | | | | | | | |
Cash flows from financing activities | | | | | | | | |
Sale of common shares | | | 40,800 | | | | 94,784 | |
Issuance of common shares | | | - | | | | 325 | |
Net cash provided (used) by financing activities | | | 40,800 | | | | 95,109 | |
| | | | | | | | |
Net change in cash | | | (2,734 | ) | | | 30,430 | |
Cash at beginning of period | | | 15,359 | | | | 114 | |
| | | | | | | | |
Cash at end of period | | $ | 12,625 | | | $ | 30,544 | |
See accompanying notes, which are an integral part of these financial statements.
CTT PHARMACEUTICAL HOLDINGS, INC.
NOTES TO THE FINANCIAL STATEMENTS
SEPTEMBER 30, 2026 (unaudited)
NOTE 1 - NATURE OF OPERATIONS
CTT Pharmaceutical Holdings, Inc. (the "Company") is a Delaware C-Corporation formed in 1996. The Company specializes in drug delivery systems technology within the pharmaceutical industry. The Company is focused on fastdissolving drug delivery systems through the development of advanced oral methods.
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of accounting
The financial statements of the Company have been prepared on the accrual basis of accounting, which conforms to accounting principles generally accepted in the United States of America (U.S. GAAP). Amounts are presented in whole U.S. dollars; totals may differ by a dollar due to rounding.
Use of estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities, at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Financial instruments
The Company's balance sheets may include the following financial instruments: cash, related-party payables, and related-party note payable. The carrying amount of current assets and current liabilities approximate their fair value due to the relatively short period of time between the origination of these instruments and their expected realization.
Revenue recognition
As of September 30, 2026, and December 31, 2025, the Company had no revenue-producing activities. The Company recognizes revenue as it satisfies contractual performance obligations by transferring promised goods or services to its customers. The amount of revenue recognized reflects the consideration the Company expects to be entitled to in exchange for those promised goods or services. A good or service is transferred to a customer when, or as, the customer obtains control of that good or service.
Earnings per share
Basic earnings per share are computed using the weighted average number of common shares outstanding during the period. The weighted average number of common shares outstanding for the three months ended September 30, 2026 and 2025 was 60,695,179 and 57,327,232, respectively. Diluted earnings per share reflect the potential dilutive effects of common stock equivalents such as options, warrants and convertible securities. Given the historical and projected future losses of the Company, all potentially dilutive common stock equivalents are considered anti-dilutive.
Concentrations of credit risk
The Company maintains cash in bank accounts at high credit quality United States financial institutions. At various times during the nine months ended September 30, 2026 and the year ended December 31, 2025, the Company may have had cash on deposit with financial institutions in excess of federal depository insurance limits. The Company has not experienced and does not anticipate any credit losses on these deposits.
Subsequent events
Management has evaluated subsequent events through the date the financial statements were available to be issued, noting no material events requiring disclosure that are not already recorded or disclosed within these financial statements.
Cash and cash equivalents
For purposes of reporting cash flows, the Company considers all liquid instruments purchased with an original maturity of three months or less to be cash equivalents. There were no cash equivalents as of September 30, 2026 and December 31, 2025.
CTT PHARMACEUTICAL HOLDINGS, INC.
NOTES TO THE FINANCIAL STATEMENTS
SEPTEMBER 30, 2026 (unaudited)
Related-party payables
Related-party payables consist of funds advanced from a related party to the Company on terms equivalent to those that prevail in arm's length transactions. During the nine months ended September 30, 2026, the Company repaid funds which were advanced by Ryan Khouri, as working capital and as part of a management contract, on an asneeded basis. The ending payable to Ryan Khouri at September 30, 2026 was $17,905.
Related-party note payable
Related-party notes consist of uncollateralized obligations of funds advanced to the Company by a related party on terms equivalent to those that prevail in arm's length transactions. There were no such advances during the nine months ended September 30, 2026 or 2025. The advances are planned to be repaid through the issuance of common restricted shares and are not formalized.
Share-based compensation
The Company recognizes compensation expenses for all share-based payments in accordance with ASC 718, Compensation - Stock Compensation. Under ASC 718, the Company calculates the fair value of stock-based awards at the grant date and recognizes the expense over the requisite service period. For third-party suppliers, the fair value is the shorter of the period over which services are to be received or the vesting period, and for employees, directors, officers and affiliates is typically the vesting period. Share-based compensation is included in consulting fees on the income statements. Shares issued for services during the three months ended September 30, 2026 were valued at the quoted market price on the date of issuance (see Note 5).
Advertising
Advertising costs are expensed as incurred and are included in operating expenses on the income statements.
Income taxes
The Company accounts for income taxes in accordance with ASC 740, Income Taxes, which requires an asset and liability approach for financial accounting and reporting of income taxes. Deferred income taxes reflect the impact of temporary differences between the amount of assets and liabilities for financial reporting purposes and such amounts as measured by tax laws and regulations. Deferred tax assets, if any, include tax loss and credit carryforwards and are reduced by a valuation allowance if, based on available evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized.
Intangible assets
The Company's intangible assets consist of trademarks and patents held across multiple countries. The patents are amortized over their useful lives, typically up to 20 years, which is the standard patent expiration period. The trademarks are amortized over their useful lives, typically up to 15 years. Costs associated with patents that have not yet received a grant number are typically recorded as deferred patent costs, and upon receipt of a grant number, are amortized.
NOTE 3 - GOING CONCERN
Historically, the Company has experienced, and the Company continues to experience, net losses from operations, negative cash flow from operating activities, and working capital deficits. These conditions raise substantial doubt about the Company's ability to continue as a going concern within one year after the date the financial statements are issued. The Company has not yet begun principal operations, and therefore, net losses are expected. The financial statements do not reflect any adjustments that might result if the Company was unable to continue as a going concern. The Company anticipates that operating losses will continue in the near term as management continues efforts to acquire income producing assets.
NOTE 4 - COMPARATIVE FINANCIAL STATEMENTS
The financial statements include certain prior-year summarized comparative information. Such information does not include all of the information required for financial statements presented in conformity with accounting principles generally accepted in the United States of America. Accordingly, such information should be read in conjunction with the Company's financial statements for the year ended December 31, 2025, and for the three months ended September 30, 2025, from which the summarized information was derived. Amounts for the three months ended September 30, 2025 were derived by subtracting the amounts reported for the six months ended June 30, 2025 from the amounts reported for the nine months ended September 30, 2025.
CTT PHARMACEUTICAL HOLDINGS, INC.
NOTES TO THE FINANCIAL STATEMENTS
SEPTEMBER 30, 2026 (unaudited)
NOTE 5 - STOCKHOLDERS' EQUITY
The Company is authorized to issue 10,000,000 shares of preferred stock. At September 30, 2026, and December 31, 2025, no shares of preferred stock were issued or outstanding. The Company is authorized to issue 150,000,000 shares of common stock. At September 30, 2026, and December 31, 2025, there were 61,516,676 and 58,837,232 shares of common stock issued and outstanding, respectively.
During the nine months ended September 30, 2026, the Company issued a total of 2,679,444 shares of common stock.
During the third quarter of 2026, the Company issued 1,794,444 shares of common stock. These issuances consisted of 750,000 shares to Ryan Khouri, 100,000 shares to Frank Hariton, 200,000 shares to Christopher Sellberg, 150,000 shares to Shay Keren, 444,444 shares to Robert Jensen, and 150,000 shares to Kevin Sakser. The shares issued to Christopher Sellberg and Robert Jensen were issued in exchange for total cash proceeds of $30,000 via private placement agreements. The 1,150,000 shares issued to Ryan Khouri, Frank Hariton, Shay Keren, and Kevin Sakser were issued in exchange for services rendered to the Company, valued at $112,000, based on the quoted market price on each issuance date ($0.10 per share for Ryan Khouri, Shay Keren, and Kevin Sakser, and $0.07 per share for Frank Hariton).
During the first quarter of 2026, the Company issued 885,000 shares of common stock. These issuances consisted of 750,000 shares to Ryan Khouri, 50,000 shares to Katherine Cole, and 85,000 shares to Kevin Sakser. The shares issued to Katherine Cole and Kevin Sakser were issued in exchange for total cash proceeds of $10,800. The shares issued to Ryan Khouri were issued in exchange for services rendered to the Company, valued at $60,000.
During 2025, the Company issued 4,767,895 shares of common stock. These issuances consisted of 2,817,895 shares to Katherine Cole, 1,650,000 shares to Ryan Khouri, 100,000 shares to Kevin Sakser, 50,000 shares to Murray Goldenberg, 100,000 shares to Borders Consulting LLC, and 50,000 shares to Frank Hariton. Included in the shares issued to Katherine Cole were 2,532,895 shares issued in exchange for cash of $95,025. All remaining shares issued during 2025 were issued in exchange for services rendered to the Company. These services were valued at $83,849.
During 2024, the Company issued 5,840,000 shares of common stock. These issuances consisted of 3,520,000 shares to Ryan Khouri, 1,250,000 shares to Allen Greenspoon, 690,000 shares to John Jennewein, 280,000 shares to Petro Czupiel, and 100,000 shares to Kevin Sakser. All shares issued during 2024 were issued in exchange for services rendered to the Company.
NOTE 6 - INTANGIBLE ASSETS
At September 30, 2026 and December 31, 2025, intangible assets were as follows:
| | September 30, 2026 | | | December 31, 2025 | |
Deferred patent costs | | $ | 4,313 | | | $ | 4,313 | |
Patents | | | 109,883 | | | | 109,883 | |
Trademarks | | | 13,564 | | | | 13,564 | |
Less: Accumulated amortization | | | (62,059 | ) | | | (56,951 | ) |
Intangible assets, net | | $ | 65,701 | | | $ | 70,809 | |
CTT PHARMACEUTICAL HOLDINGS, INC.
NOTES TO THE FINANCIAL STATEMENTS
SEPTEMBER 30, 2026 (unaudited)
Amortization expense for the three months and nine months ended September 30, 2026 was $1,703 and $5,109, respectively, and for the year ended December 31, 2025 was $6,432.
On August 11, 2026, the United States Patent Office issued Patent No. 12,702,645 on the Company's continuation-inpart (CIP) application utilizing the Company's technology for a nicotine strip. The Company's patents are listed below:
Country | Patent No. | File Date | Expiration Date |
Canada | 2624110 | 3/27/2008 | 3/27/2028 |
U.S. | 8623401 | 3/27/2008 | 3/27/2028 |
U.S. | 9833461 | 10/23/2015 | 10/23/2035 |
Canada | 2922959 | 3/3/2016 | 3/3/2036 |
U.S. (Parent) | 11166912 | 3/3/2016 | 3/3/2036 |
Europe | 3423037 | 2/27/2017 | 2/27/2037 |
Mexico | 391622 | 2/27/2017 | 2/27/2037 |
U.S. (Nicotine CIP) | 12,702,645 | 3/3/2016 | 3/3/2036 |
United Kingdom | 3423037 | 2/27/2017 | 2/27/2037 |
Unitary Patent | 3423037 | 2/27/2017 | 2/27/2037 |
The Company also has three trademarks, one in Canada and two in the U.S. The Canada trademark was filed on 11/28/2017 and expires on 11/28/2032. The U.S. trademarks were filed on 5/28/2018 and 11/28/2019 and expire on 5/28/2033 and 11/28/2034, respectively.
Intangible assets are recorded at cost and subsequently amortized over the respective useful lives of each, as reflected on the balance sheets. Management believes the reflected value of the intangible assets would substantially increase upon completion of a third-party appraisal.
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
Our principal asset is the remaining book value of our patents which we do not believe reflects their potential value after development. Our Net Loss increased from ($15,379) during the three months ended September 30, 2025 to ($127,064) during the three months ended September 30, 2026, an increase of $111,675. The principal driver of this change was the increase in consulting fees from $5,000 in the 2025 period to $112,000 in the 2026 period. The principal reasons for the increase were: (i) costs associated with being a 1934 Act Reporting Company during the 2026 period; (ii) certain non-recurring consulting fees that were paid in shares valued at $0.10 per share during the 2026 period; and (iii) that we accrued and did not pay certain costs during the 2025 period.
As is clear from the foregoing, we have had minimal operations during the above periods and the specific components of our results have and are likely to fluctuate greatly until we establish manufacturing operations. We do not believe they provide any meaningful insight as to operations we will conduct in the future.
Going Concern
Our independent registered auditors included an explanatory paragraph in their opinion on our financial statements as of and for the fiscal year ended December 31, 2025, that states that our ongoing losses and lack of resources cause reasonable doubt about our ability to continue as a going concern.
Critical Accounting Policies
A summary of our significant accounting policies is included in Note 1 of the “Notes to the Consolidated Financial Statements,” contained elsewhere in this prospectus. Management believes that the consistent application of these policies enables us to provide users of the financial statements with useful and reliable information about our operating results and financial condition. The summary condensed financial statements are prepared in accordance with accounting principles generally accepted in the U.S., which require us to make estimates and assumptions.
Disclosure of controls and procedures.
We maintain disclosure controls and procedures that are designed to ensure that information required to be in this prospectus, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, control may become inadequate because of changes in conditions or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.
As required by the SEC Rule 13a-15(b), we carried out an evaluation under the supervision and with the participation of our management, including our principal executive officer who is also our principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on the foregoing, our principal executive and financial officer concluded that our disclosure controls and procedures were not effective at a reasonable assurance level due to the material weaknesses described below.
In light of the material weaknesses described below, we performed additional analysis and other post-closing procedures to ensure our financial statements were prepared in accordance with generally accepted accounting principles. Accordingly, we believe that the financial statements included in this report fairly present, in all material respects, our financial condition, results of operations and cash flows for the periods presented.
A material weakness is a control deficiency (within the meaning of the Public Company Accounting Oversight Board (PCAOB) Auditing Standard No. 2) or combination of control deficiencies that result in more than a remote likelihood that a material misstatement of the annual or interim financial statements will not be prevented or detected.
Management has identified the following two material weaknesses which have caused management to conclude that as of December 31, 2025, our disclosure controls and procedures were not effective at the reasonable assurance level:
1. We do not have written documentation of our internal control policies and procedures. Written documentation of key internal controls over financial reporting is a requirement of Section 404 of the Sarbanes-Oxley Act, which is applicable to us for the year ended December 31, 2025. Management evaluated the impact of our failure to have written documentation of our internal controls and procedures on our assessment of our disclosure controls and procedures and has concluded that the control deficiency that resulted represented a material weakness.
2. We do not have sufficient segregation of duties within accounting functions, which is a basic internal control. Due to our size and nature, segregation of all conflicting duties may not always be possible and may not be economically feasible. However, to the extent possible, the authorization of transactions, the custody of assets and the recording of transactions should be performed by separate individuals. The recording of transactions function is maintained by a third-party consulting firm whereas authorization and custody remain under the Company’s Chief Executive Officer’s responsibility. Management evaluated the impact of our failure to have segregation of duties on our assessment of our disclosure controls and procedures and has concluded that the control deficiency that resulted represented a material weakness.
To address these material weaknesses, management performed additional analyses and other procedures to ensure that the financial statements included herein fairly present, in all material respects, our financial position, results of operations and cash flows for the periods presented.
Changes in internal controls over financial reporting.
There has been no change in our internal control over financial reporting that occurred during the periods set forth in this prospectus. As our resources allow, we will engage additional personnel to address these deficiencies.
Plan of Operations.
During calendar 2026 we intend to use approximately $500,000 obtained through the ELOC, other investment or commercial financing (none of which can be assured) to establish a manufacturing facility. If we are unsuccessful in those efforts, our operations will continue in a manner similar to our current operations.
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
As a smaller reporting company we are not required to respond to this item.
Item 4. Controls and Procedures.
Included in our response to Item 2 and incorporated by reference.
PART II—OTHER INFORMATION
Item 1. Legal Proceedings.
We are not party to any legal proceedings.
Item 1A. Risk Factors.
As a smaller reporting company we are not required to respond to this item.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
As a smaller reporting company we are not required to respond to this item.
Item 3. Defaults Upon Senior Securities.
None
Item 4. Mine Safety Disclosures.
None
Item 5. Other Information.
None
Item 6. Exhibits.
The following exhibits are included as part of this report by reference:
No. | | Description |
31.1 | | Certification of Chief Executive Officer and Chief Financial Officer pursuant to Securities Exchange Act of 1934 Rule 13a-14(a) or 15d-14(a). |
32.1 | | Certifications pursuant to Securities Exchange Act of 1934 Rule 13a-14(b) or 15d-14(b) and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
101.INS | | Inline XBRL Instance Document |
101.SCH | | Inline XBRL Taxonomy Extension Schema |
101.CAL | | Inline XBRL Taxonomy Extension Calculation Linkbase |
101.DEF | | Inline XBRL Taxonomy Extension Definition Linkbase |
101.LAB | | Inline XBRL Taxonomy Extension Label Linkbase |
101.PRE | | Inline XBRL Taxonomy Extension Presentation Linkbase |
104 | | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| | CTT PHARMACEUTICAL HOLDINGS, INC. | |
| | | | |
November 16, 2026 | | By: | /s/ Ryan Khouri | |
Date | | Name: | Ryan Khouri | |
| | Title: | Chief Executive Officer (Principal Executive, Financial and Accounting Officer) | |